$Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study$

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to aberrant histone methylation, oncogenic transformation, and a proliferative dependency on EZH2 activ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2018-05, Vol.19 (5), p.649-659
Hauptverfasser:	Italiano, Antoine, Soria, Jean-Charles, Toulmonde, Maud, Michot, Jean-Marie, Lucchesi, Carlo, Varga, Andrea, Coindre, Jean-Michel, Blakemore, Stephen J, Clawson, Alicia, Suttle, Benjamin, McDonald, Alice A, Woodruff, Mark, Ribich, Scott, Hedrick, Eric, Keilhack, Heike, Thomson, Blythe, Owa, Takashi, Copeland, Robert A, Ho, Peter T C, Ribrag, Vincent
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anorexia Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Asthenia Benzamides - administration & dosage Benzamides - adverse effects Benzamides - pharmacokinetics Cancer Cell cycle Children Clinical trials Dose-Response Relationship, Drug Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Enhancer of Zeste Homolog 2 Protein - metabolism Enzyme Inhibitors - administration & dosage Enzyme Inhibitors - adverse effects Enzyme Inhibitors - pharmacokinetics Female France Gene expression Genetic transformation Humans Lymphocytes B Lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - enzymology Lymphoma, B-Cell - pathology Male Maximum Tolerated Dose Medical prognosis Methylation Middle Aged Mutation Nausea Patients Pharmacodynamics Pharmacokinetics Population studies Protein expression Pyridones - administration & dosage Pyridones - adverse effects Pyridones - pharmacokinetics Safety Sarcoma Solid tumors Sucrose Thrombocytopenia Time Factors Toxicity Treatment Outcome Tumors Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!